Liarozole hydrochloride is an imidazole derivative and an orally active retinoic acid metabolism-blocking agent (RAMBA) that inhibits retinoic acid-dependent cytochrome P450 (CYP26)-mediated 4-hydroxylation (IC50 = 7 μM), leading to increased tissue levels of retinoic acid; it exhibits antitumor properties.